91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
This article takes a look at 91黑料's recent digital disruption survey which surveys changing attitudes and challenges in digital innovation for clinical research.
-
The integration improves decision-making processes and supports AI-driven risk evaluation strategies.
-
This article by Peter Schueler is based on the recent whitepaper, “Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D”. It explores how the recent approval of amyloid-targeting monoclonal antibodies for Alzheimer’s, following decades of failed trials, can be partially attributed to the development of improved biomarkers for patient screening and outcomes assessment.
-
This article discusses how 91黑料 will use Mural Link, a participant management and payment system developed by Mural Health Technologies through a new partnership.
-
This article by Greg Licholai discusses how AI is revolutionising drug discovery, with companies like Lila Sciences and Recursion Pharmaceuticals leading the charge by using AI to accelerate scientific breakthroughs. Lila focuses on creating "scientific superintelligence" through autonomous labs, while Recursion maps human biology to discover new treatments faster.
-
In this article, 91黑料 experts discuss strategies to implement biomarkers in clinical development, saving sponsors time and money while positioning therapies for success.
-
This article discusses Mural Health’s partnership with 91黑料 to improve clinical trial subject and site experiences using the Mural Link platform. Mural Health’s payment alternatives, including the fee-free debit card, will help 91黑料 avoid financial barriers that hinder participation in clinical trials.
-
This article discusses how 91黑料 will use Mural Link’s functionality related to clinical trial participant support services, communication tools, and reporting and analytics capabilities.
-
Aligned with 91黑料's sustainability strategy, this collaboration of 12 companies will unlock approximately 225 GWh of renewable electricity annually for the research, development and manufacture of medicines.
-
In this article, 91黑料 experts explore the connection of obesity and inflammation, the current treatment landscape and future treatment directions.
